Alf Gunnar Martin Nicklasson

Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden.

Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets.

POZEN, Inc. manufactures and markets pharmaceutical products. Its Pipeline products are PA Product Portfolio, which is focused on integrated aspirin therapies that enable the full power of aspirin by reducing its potential gastrointestinal damage. The firm PA Product Portfolio consists of PA8140 and PA32540. The company was founded by John R. Plachetka in 1996 and is headquartered in Raleigh, NC.

Sanivo Pharma AS provides pharmaceutical products and services. It offers analysis missions, subcontracting and repacking of medicines for clinical trials. The company was founded in 1995 and is headquartered in Oslo, Norway.

Denator AB provides instruments and consumables that stabilize biological samples. It develops, markets and sells instruments and consumables to address needs in the life science and clinical research markets. The firm's products enable scientists to stabilize biological samples, such as tissue sections or cellular biopsies, from the moment of sampling. The company was founded by Olof Sköld and Karl Sköld in 2004 and is headquartered in Göteborg, Sweden.

The Royal Swedish Academy of Engineering Sciences (IVA) is an organization that brings together around 1,300 academy members and 250 companies to bridge the gap between academia, business, and politics. The non-profit company is based in Stockholm, Sweden. The Swedish company's aim is to work towards people's ability to contribute positively to society. The organization runs an internship program called Tekniksprånget, which gives young people in Sweden the opportunity to test the engineering profession through a four-month paid internship. The program has been running since 2012 and aims to inspire more people to choose a higher technical education. The CEO of the company is Björn O. Nilsson.

AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden.

Hjärt-Lungfonden Svenska Nationalföreningen mot hjärt is a non-profit organization based in Stockholm, Sweden. and has subsidiaries in Sweden. The organization's main objective is to raise funds for selected Swedish heart and lung research to help people live longer and healthier lives. The Swedish company works together with individuals and companies to collect and distribute funds for heart and lung research. The organization's vision is to create a world free from heart and lung disease. Kärlkramp, which is a temporary reduction of blood flow in the heart's coronary vessels and the main symptom is a squeezing chest pain, is one of the diseases they focus on.

Stockholm Chamber of Commerce is a member of Swedish Chambers International, which is an umbrella organization for Swedish Chambers of Commerce abroad. The Chamber of Commerce in Stockholm provides contact information for those who are unsure of who to contact regarding their matter. The non-profit company is based in Stockholm, Sweden, and has subsidiaries in Sweden. The purpose of SCI is to strengthen the brand internationally, facilitate business for companies, and exchange experiences.

Premier Research Group Ltd. provides contract research services to pharmaceutical industry. It engages in analgesics, neuroscience, medical devices, rare diseases and pediatrics. The company offers pediatric experience with both familiar and extremely rare childhood illnesses, including work at PICUs, NICUs, clinics, ERs and neonatal studies. Premier Research Group was founded in 2002 and is headquartered in Wokingham, the United Kingdom.

EffRx Pharmaceuticals SA manufactures and distributes specialty pharmaceutical products. The firm's focus areas include metabolic bone disease, oncology supportive care, pediatric medication, and medical support to companies in life cycle management. It also engages in licensing agreements and distribution and commercialization partnerships. The company was founded by Christer Ros?n in 1998 and is headquartered in Freienbach, Switzerland.

Farma Investment AS invests in shares and real properties. The company was founded on June 23, 2011 and is headquartered in Oslo, Norway.

Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.

Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.